Pavel Rodyukov is a seasoned venture capitalist, with over 16 years of experience in the field. He has been practicing venture capital investment since 2004, and has been associated with RUSNANO, a Russian state-owned investment fund, since 2008. Rodyukov is highly skilled in the full cycle management of the investment process, from deal origination to hands-on management and trade sale. He has served as a board member for four portfolio companies, including Trackpore Technology, HemaCore, Mitotech LLC, and RusnanoMedInvest, and as a non-executive director for Mitotech S.A. In addition, Rodyukov is a member of the Strategy Committee at NovaMedica, a joint venture between Rusnano and Domain Associates. He has been involved in established business operations in Russia, North America, Israel, and the EU.

Rodyukov has a strong educational background, having studied both Certificate of the 1.0 and 5.0 Series at Federal Financial Markets Service and a Master of Science in Business Administration and Management, General, at Bauman Moscow State Technical University.

Currently, Rodyukov serves as a partner at MAXMODAL and has previously held positions as CEO of RusnanoMedInvest, investment director at RUSNANO, and senior investment manager at NM Trust Asset Management, Universal Asset Management, and Sistema-Venture. He has also served as a board observer for companies such as binx health, Epic Sciences, and OCON Medical.